
|Articles|February 1, 2016
- Pharmaceutical Executive-02-01-2016
- Volume 36
- Issue 2
Pharmaceutical Executive, February 2016 Issue (PDF)
Click the title above to open the Pharmaceutical Executive February 2016 issue in an interactive PDF format.
Advertisement
Articles in this issue
almost 10 years ago
Life and Lipitor: Pfizer's Traci Medford-Rosowalmost 10 years ago
The Staying Power of Emerging Marketsalmost 10 years ago
Canada's Rx&D: Fresh Start for a New Eraalmost 10 years ago
Morgan Moments: A Closer Reading of the JP Morgan Investor Conferencealmost 10 years ago
Pharma dot-gov: A New Business Modelalmost 10 years ago
The Creative Impulse: Defending Pharma and Health DTCalmost 10 years ago
Securing Cipla’s Futurealmost 10 years ago
Country Report: South AfricaNewsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Pfizer’s Stock Reacts to Decreases in 2026 Revenue Projections in Full-Year 2026 Guidance Release
2
Roundup: Harbor BioMed Announces Collaboration and License Agreement with Bristol Myers, Squibb, VYNE Therapeutics Enters Merger Agreement with Yarrow Bioscience
3
Novo Nordisk Submits NDA to FDA for CagriSema
4
Four Republicans Break with House GOP to Force Vote on Extending ACA Tax Credits
5




